DrugPatentWatch Database Preview
Salix Pharms Company Profile
What is the competitive landscape for SALIX PHARMS, and when can generic versions of SALIX PHARMS drugs launch?
SALIX PHARMS has twelve approved drugs.
There are forty-five US patents protecting SALIX PHARMS drugs.
There are four hundred and sixty-nine patent family members on SALIX PHARMS drugs in fifty-three countries and forty-eight supplementary protection certificates in nine countries.
Summary for Salix Pharms
| International Patents: | 469 |
| US Patents: | 45 |
| Tradenames: | 10 |
| Ingredients: | 9 |
| NDAs: | 12 |
Drugs and US Patents for Salix Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 022554-001 | Mar 24, 2010 | RX | Yes | Yes | 7,935,799 | ➤ Sign Up | ➤ Sign Up | ||||
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 022554-001 | Mar 24, 2010 | RX | Yes | Yes | 8,969,398 | ➤ Sign Up | ➤ Sign Up | ||||
| Salix Pharms | METOZOLV ODT | metoclopramide hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 022246-002 | Sep 4, 2009 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Salix Pharms | RELISTOR | methylnaltrexone bromide | SOLUTION;SUBCUTANEOUS | 021964-002 | Sep 27, 2010 | RX | Yes | Yes | 8,552,025 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Salix Pharms | XIFAXAN | rifaximin | TABLET;ORAL | 022554-001 | Mar 24, 2010 | RX | Yes | Yes | 8,158,781 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Salix Pharms | RELISTOR | methylnaltrexone bromide | SOLUTION;SUBCUTANEOUS | 021964-001 | Apr 24, 2008 | RX | Yes | Yes | 8,552,025 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Salix Pharms Inc | RELISTOR | methylnaltrexone bromide | TABLET;ORAL | 208271-001 | Jul 19, 2016 | RX | Yes | Yes | 9,492,445 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Salix Pharms
Paragraph IV (Patent) Challenges for SALIX PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Oral Solution | 100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch | ➤ Subscribe | 2007-11-27 |
| ➤ Subscribe | Injection | 8 mg/0.4 mL | ➤ Subscribe | 2015-09-08 |
| ➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-08-24 |
| ➤ Subscribe | Tablets | 550 mg | ➤ Subscribe | 2015-12-18 |
| ➤ Subscribe | Injection | 12 mg/0.6 mL | ➤ Subscribe | 2015-07-22 |
| ➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2016-09-06 |
| ➤ Subscribe | Tablets | 1.102 g and 0.398 g | ➤ Subscribe | 2008-04-09 |
Non-Orange Book US Patents for Salix Pharms
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,615,207 | Methods for treating irritable bowel syndrome | ➤ Sign Up |
| 8,388,935 | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions | ➤ Sign Up |
| 7,244,412 | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia | ➤ Sign Up |
| 7,585,838 | Methods of treating fibromyalgia caused by small intestinal bacterial overgrowth | ➤ Sign Up |
| 5,977,175 | Methods and compositions for improving digestion and absorption in the small intestine | ➤ Sign Up |
| 9,358,276 | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions | ➤ Sign Up |
| 8,507,009 | Colonic purgative composition with soluble binding agent | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Salix Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1116372 | ➤ Sign Up |
| Ukraine | 111717 | ➤ Sign Up |
| Japan | 2006522818 | ➤ Sign Up |
| Russian Federation | 2571268 | ➤ Sign Up |
| Japan | 2005509588 | ➤ Sign Up |
| Yugoslavia | 24804 | ➤ Sign Up |
| South Korea | 20070113326 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Salix Pharms Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90020-1 | Sweden | ➤ Sign Up | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
| C0033 | France | ➤ Sign Up | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705 |
| C/GB98/031 | United Kingdom | ➤ Sign Up | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| C/GB07/011 | United Kingdom | ➤ Sign Up | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| C/GB02/037 | United Kingdom | ➤ Sign Up | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| C/GB98/040 | United Kingdom | ➤ Sign Up | PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508 |
| 14/058 | Ireland | ➤ Sign Up | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
